Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP
Patent Provides Coverage for Lpath's Anti-S1P Antibody in the Treatment of a
Wide Variety of Ocular Disorders, Including Wet AMD
SAN DIEGO, May 30, 2013 (GLOBE NEWSWIRE) -- Lpath, Inc. (Nasdaq:LPTN), the
industry leader in bioactive lipid-targeted therapeutics, received official
notification from the U.S. Patent and Trademark Office (USPTO) that the
Company has been issued a key patent supporting its iSONEP program.
The newly issued U.S. patent, No. 8,444,970, is entitled, "Compositions and
Methods for the Treatment and Prevention of Ocular Conditions." It claims
methods of using monoclonal antibodies (including iSONEP™) that bind
sphingosine-1-phosphate (S1P) in the treatment of a wide variety of ocular
conditions, including wet AMD (Age-related Macular Degeneration).
"This patent provides exclusivity for iSONEP and other antibodies to S1P in
the U.S. for ocular disorders and complements our recent exclusivity for
anti-S1P antibodies in Europe for wet AMD, cancer, and other conditions," said
Roger Sabbadini, Lpath's vice president, founder, and an inventor of the
Lpath is conducting a Phase 2 clinical trial for iSONEP, called Nexus, which
is evaluating the anti-S1P antibody's safety and efficacy in wet-AMD patients.
Lpath entered into an agreement with Pfizer in 2010 that provides Pfizer an
exclusive option for a worldwide license to develop and commercialize iSONEP.
Additionally, Lpath is independently conducting an ASONEP™ Phase 2 trial in
renal cell carcinoma patients.
iSONEP and ASONEP are different formulations of sonepcizumab, a first-in-class
therapeutic antibody against S1P developed using Lpath's ImmuneY2™
drug-discovery engine. Antibodies developed via this discovery engine are
designed to target bioactive signaling lipids, such as S1P, that are involved
in cancer, AMD, inflammatory and auto-immune disorders, and many other
About Lpath's Patent Portfolio
Over the course of the Company's development, Lpath has achieved a broad and
deep intellectual property position in the bioactive-lipid area. The Company's
comprehensive patent portfolio now includes over 25 issued patents and over 25
patent applications in the U.S., with corresponding international patents and
applications. These patents primarily relate to the use of reagents and
methods designed to interfere with the actions of bioactive lipids involved in
human disease. Lpath's intellectual property portfolio includes coverage of
compositions of matter that specifically bind to sphingolipids and
sphingolipid metabolites. These compositions, including antibodies, could be
used in the diagnosis and treatment of various diseases and disorders,
including cardiovascular and cerebrovascular disease, cancer, inflammation,
autoimmune disorders, ocular disease, and angiogenesis.
Lpath has also obtained issued patent claims on sphingolipid targets (e.g.,
receptors and signaling sphingolipids) and methods for using such targets in
drug-discovery screening efforts.
The Company believes that its patent portfolio provides broad and commercially
significant coverage of antibodies, receptors, enzymes, and other moieties
that bind to a lysolipid (or a sphingolipid metabolite) for diagnostic,
therapeutic, and screening purposes.
San Diego-based Lpath, Inc., a therapeutic antibody company, is the category
leader in lipid-targeted therapeutics. The Company's ImmuneY2™ drug-discovery
engine has the unique ability to generate monoclonal antibodies that bind to
and inhibit bioactive lipids that contribute to disease. The Company is
developing three drug candidates: iSONEP™ is being studied in a Phase 2 trial
in wet AMD patients; ASONEP™ is being studied in a Phase 2 trial in renal cell
carcinoma patients; and Lpathomab is a preclinical drug candidate that holds
promise in pain, neurotrauma, and other diseases. For more information, visit
About Forward-Looking Statements
The Company cautions you that the statements included in this press release
that are not a description of historical facts are forward-looking statements.
These include statements regarding: the protection against competition
afforded by issued patents; the eventual commercial viability of the Company's
drug programs; and the Company's ability to complete additional discovery and
development activities for drug candidates utilizing its proprietary ImmuneY2
drug discovery process. Actual results may differ materially from those set
forth in this press release due to the risks and uncertainties inherent in the
Company's business, including, without limitation: the outcome of the final
analyses of the data from the Phase 1 clinical trial may vary from the
Company's initial conclusions; the results of any future clinical trials for
iSONEP or ASONEP may not be favorable and the Company may never receive
regulatory approval for iSONEP or ASONEP or any of its drug candidates; and
the Company may not be able to secure the funds necessary to support its
clinical trial and product development plans. More detailed information about
the Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings with the
Securities and Exchange Commission, including its Annual Report on Form 10-K
and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may
be read free of charge on the SEC's web site at www.sec.gov. You are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and the Company undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof. This caution is made under the safe
harbor provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.
CONTACT: Lpath, Inc.
Scott R. Pancoast
President & CEO
Lpath Investor Relations
Press spacebar to pause and continue. Press esc to stop.